Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SP-8008 in Healthy Male Subjects
NCT04770194Phase 1Completed
- Sponsor
- Shinpoong Pharma
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SP-8008 in acute coronary syndrome (ACS) and stroke (6 cohorts), sponsored by Shinpoong Pharma. Primary endpoints: Serious Adverse Drug Reactions up to 7 days, Severe Adverse Drug Reactions up to 7 days and 1 more. Started Oct 2019; status: completed.
02
Drugs
SP-8008
03
Conditions
acute coronary syndrome (ACS)stroke
Beyond the preview
Go deeper on NCT04770194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770194.